IL-17A

Muge Didem Orhan1,2,3, Lalehan Oktay4,5, Ayşe Irem Cınar6

  • 1Neuroscience, Graduate School of Education, Bahçeşehir University, Istanbul 34353, Turkey.

ACS chemical neuroscience
|September 9, 2025
PubMed
概括

尼拉巴是一种PARP-1抑制剂,通过阻断促炎性IL-17A细胞因子与其受体的相互作用,显示出治疗多发性硬化症 (MS) 的潜力. 这项研究证明了Niraparib.